FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology

Advanced search


Full Text:


Aims of the study: to assess health care costs of the use of biological agents (vedolizumab and various TNF-α inhibitors) in adult patients with moderate to severe active ulcerative colitis (UC) and moderate or severe active Crohn’s disease (CT) with an unsatisfactory response, loss of response, or intolerance to one or more chemotherapeutic agents, and TNF-α inhibitors.

Materials and Methods. Statistical analysis, published reports on inflammatory bowel disease (IBD) treatment, the highest quoted prices of drugs from the list of vital and essential drugs (VED), the size of the maximal wholesale mark-ups, and the regulations of financial expenses in the Russian Federation Health system in 2016, were used in this analysis. Since Vedolizumab has been just recently registered in theRussian Federation and it is yet to be included in the VED, for now the drug has no quoted price. Therefore, we used the price suggested by the manufacturer added with the wholesale markup and VAT.

Results. As compared with the biological agents-TNF-α inhibitors currently used in the treatment of adult patients with moderate to severe active UC and moderate to severe active CD who showed an unsatisfactory response, loss of response or intolerance of one or more components of standard therapy, or TNF-α inhibitors, the introduction of Vedolizumab with shares of 3%, 4% and 7% for the first, second and third year is expected to result in cost savings of 26.4 million rubles (0.62%) for UC and 21.5 million rubles (0.63%) for CD.

About the Author

E. A. Pyadushkina
The Russian Presidential Academy of National Economy and Public Administration, Moscow
Russian Federation

Pyadushkina Elena Aleksandrovna – research fellow of Laboratory for health technology assessment of Applied economic research Institute.

Address: Vernadskogo prospect, 82-1, Moscow, Russia, 119571


1. Improve the medical care for patients with inflammatory bowel disease. The proceedings of the meeting of the expert Council on healthcare of the Federation Council Committee on social policy [Sovershenstvovanie okazaniya meditsinskoi pomoshchi bol’nym s vospalitel’nymi zabolevaniyami kishechnika. Sbornik materialov zasedaniya ekspertnogo soveta po zdravookhraneniyu Komiteta Soveta Federatsii po sotsial’noi politike (in Russian)]. Moscow. 2016; 77s.

2. Veselov A.V., Veselov V.V., Zapol’skiĭ A.G. Meditsinskie tekhnologii. Otsenka i vybor. 2015; 1 (19): 38-42.

3. Clinical guidelines of the Russian gastroenterological Association and the Association of Coloproctology Russia on the diagnosis and treatment of ulcerative colitis in adults. Accessed: 07.02.2017.

4. National Health Service. Ulcerative colitis – Treatment. 2016. Accessed: 17.09. 2016.

5. Rutgeerts P., Sandborn W. J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353 (23): 2462-76.

6. Sandborn W. J., Van A.G., Reinisch W., Colombel J. F., D’Haens G., Wolf D.C., et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012; 142 (2): 257-65.

7. Sandborn W. J., Feagan B.G., Marano C., Zhang H., Strauss R., Johanns J., et al.; PURSUIT-SC Study Group. Subcutaneous golimumab induces clinical response and remission in patients with moderate-tosevere ulcerative colitis. Gastroenterology. 2014; 146 (1): 85-95.

8. Feagan B.G., Rutgeerts P., Sands B. E., Hanauer S., Colombel J.F., Sandborn W.J., Van Assche G., Axler J., Kim H.J., Danese S., Fox I., Milch C., Sankoh S., Wyant T., Xu J., Parikh A.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22; 369 (8): 699-710. DOI:10.1056/NEJMoa1215734.

9. Klinicheskie rekomendatsii Rossiĭskoĭ gastroenterologicheskoĭ Assotsiatsii i Assotsiatsii koloproktologov Rossii po diagnostike i lecheniyu bolezni Krona. 2017 god. Accessed: 07.02.2017.

10. World Gastroenterology Organisation global guidelines for Inflammatory Bowel Disease, 2015. Accessed:15.02.2016.

11. Gomollón F., Dignass A., Annese V., Tilg H., Van Assche G., Lindsay J.O. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2016; 11 (1): 3-25. Accessed: 15.02.2016.

12. Hanauer S.B. Clinical perspectives in Crohn’s disease. Turning traditional treatment strategies on their heads: current evidence for “stepup” versus “top-down”. Rev Gastroenterol Disord. 2007; 7 (2): 17-22.

13. Ricart E., García-Bosch O., Ordás I., Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol. 2008; 14 (36): 5523-7.

14. Hanauer S.B., Feagan B.G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-9.

15. Sandborn W.J., Feagan B.G., Stoinov S., et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007; 357: 228-38.

16. Sandborn W. J., Hanauer S.B., Rutgeerts P., et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-9.

17. Sandborn W. J., et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. New England Journal of Medicine. 2013; 369 (8): 711-721.

18. Stidham R.W., et al. Systematic review with network metaanalysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment. Pharmacol. Ther. 2014; 39: 1349-1362.

19. Sura M.V. Meditsinskie tekhnologii. Otsenka i vybor. 2016; 1 (23): 24-34.

20. Federal state statistics service. Demographics. The population estimate of January 1, 2016 and on average for 2015. Accessed: 10.06.2016.

21. Bulletin of the Federal state statistics service, “Regions of Russia. Socio – economic indicators, 2012” [Byulleten’ Federal’noi sluzhby gosudarstvennoi statistiki «Regiony Rossii. Cotsial’noekonomicheskie pokazateli – 2012 g» (in Russian)].

22. Belousova E., Khalif I. Tu1290 Social, Demographic and Clinical Features of Inflammatory Bowel Disease in Russia. Gastroenterology. 2012; 142 (5): 794.

23. The state register of maximum ex-works manufacturers ‘ prices for the medicinal preparations included into the list of vital and essential medicinal products Accessed: 10.08.2016.

24. The limiting sizes of wholesale and retail markups to the prices for vital and essential pharmaceuticals established in constituent entities of the Russian Federation (data for the 2nd quarter of 2016) site of the Federal Antimonopoly service of Russia. Accessed: 21.07.2016.

25. Instructions for use of medicinal product for medical use Remicade. Reg.: P-N012948/01-240713. Accessed: 20.09.2016.

26. Instructions for use of medicinal product for medical use Simponi. Reg.: PL-001686-251213. Accessed: 20.09.2016.

27. Instructions for use of medicinal product for medical use, Antivi. Reg.: LS-003697-220616. Accessed: 20.09.2016.

28. Instructions for use of medicinal product for medical use Humira. Reg.: LS-002422-290915. Accessed: 20.09.2016.

29. Instructions for use of the medicinal product for medical use, Cimzia. Reg.: LS-000008-240914. Accessed: 20.09.2016.

30. Resolution of the Government of the Russian Federation of 19 December 2015. N 1382 “On the programme of state guarantees of free rendering to citizens of medical aid for 2016” [Postanovlenie Pravitel’stva Rossiiskoi Federatsii ot 19 dekabrya 2015g. N 1382 «O programme gosudarstvennykh garantii besplatnogo okazaniya grazhdanam meditsinskoi pomoshchi na 2016 god» (in Russian)].

31. Mauskopf J.A., Sullivan S.D., Annemans L., et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices – budget impact analysis. Value in health. 2007; 10 (5): 336-347.

32. Guidelines for the assessment of the impact of the budget in the framework of the Program of state guarantees of free rendering to citizens of medical aid. The order of the fgbi “ZECKE” Ministry of health of Russia from 23.12.2016 No. 145-od. Accessed: 28.12.2016.

33. Gordon J.P., McEwan P.C., Maguire A., Sugrue D.M., Puelles J. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015; 27: 804-12.

34. Sands B.  E., Dubinsky M.C., Vermeire S., Sankoh S., Rosario M., Milch C. Effects of increased vedolizumab dosing frequency on clinical remission and response in ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis. 2014; 20 (1): 1-67.

35. Raluy-Callado M., Li Q. Luo M., Lasch K. Khalid J.M. P0856 Patterns of dose escalation amongst patients with ulcerative colitis and Crohn’s disease treated with vedolizumab vs. infliximab in the United States (US). (UEGW 2016). United European Gastroenterology Journal. 3(5S): A447-A448. Accessed: 26.10.2016.


For citations:


Views: 1418

ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)